Talis Biomedical Corporation Research and Development Expense
Talis Biomedical Corporation reported Research and Development Expense of $1.60 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-08-19
- Talis Biomedical Corporation research and development expense for the quarter ending 2024-06-30 was $1.60M, a 84.83% decline year-over-year.
- Talis Biomedical Corporation research and development expense for the quarter ending 2024-03-31 was $2.53M, a 81.64% decline year-over-year.
- Talis Biomedical Corporation research and development expense for the quarter ending 2023-12-31 was $8.04M, a 47.24% decline year-over-year.
- Talis Biomedical Corporation research and development expense for the quarter ending 2023-09-30 was $8.30M, a 52.62% decline year-over-year.
- Talis Biomedical Corporation research and development expense for fiscal 2023 was $40.69M, a 42.55% decline from fiscal 2022.
- Talis Biomedical Corporation research and development expense for fiscal 2022 was $70.83M, a 55.05% decline from fiscal 2021.
- Talis Biomedical Corporation research and development expense for fiscal 2021 was $157.59M, a 77.03% increase from fiscal 2020.
- Talis Biomedical Corporation research and development expense for fiscal 2020 was $89.02M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $1.60M 10-Q · filed 2024-08-19 | $4.13M 10-Q · filed 2024-08-19 | $12.18M derived: sum of 3 quarters · filed 2024-08-19 | $20.48M derived: sum of 4 quarters · filed 2024-08-19 |
| 2024-03-31 | $2.53M 10-Q · filed 2024-05-08 | $10.57M derived: sum of 2 quarters · filed 2024-05-08 | $18.88M derived: sum of 3 quarters · filed 2024-05-08 | $29.43M derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-12-31 | $8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $16.34M derived: sum of 2 quarters · filed 2024-03-28 | $26.90M derived: sum of 3 quarters · filed 2024-08-19 | $40.69M 10-K · filed 2024-03-28 |
| 2023-09-30 | $8.30M 10-Q · filed 2023-11-14 | $18.86M derived: sum of 2 quarters · filed 2024-08-19 | $32.65M 10-Q · filed 2023-11-14 | $47.90M derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-06-30 | $10.55M 10-Q · filed 2024-08-19 | $24.35M 10-Q · filed 2024-08-19 | $39.59M derived: sum of 3 quarters · filed 2024-08-19 | $57.11M derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-03-31 | $13.80M 10-Q · filed 2024-05-08 | $29.04M derived: sum of 2 quarters · filed 2024-05-08 | $46.56M derived: sum of 3 quarters · filed 2024-05-08 | $63.92M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $15.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $32.76M derived: sum of 2 quarters · filed 2024-03-28 | $50.13M derived: sum of 3 quarters · filed 2024-03-28 | $70.83M 10-K · filed 2024-03-28 |
| 2022-09-30 | $17.52M 10-Q · filed 2023-11-14 | $34.89M derived: sum of 2 quarters · filed 2023-11-14 | $55.59M 10-Q · filed 2023-11-14 | $72.65M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $17.36M 10-Q · filed 2023-08-10 | $38.07M 10-Q · filed 2023-08-10 | $55.13M derived: sum of 3 quarters · filed 2023-08-10 | $80.97M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $20.70M 10-Q · filed 2023-05-11 | $37.77M derived: sum of 2 quarters · filed 2023-05-11 | $63.61M derived: sum of 3 quarters · filed 2023-05-11 | $118.10M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $17.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $42.90M derived: sum of 2 quarters · filed 2023-03-22 | $97.40M derived: sum of 3 quarters · filed 2023-03-22 | $157.59M 10-K · filed 2023-03-22 |
| 2021-09-30 | $25.84M 10-Q · filed 2022-11-03 | $80.34M derived: sum of 2 quarters · filed 2022-11-03 | $140.53M 10-Q · filed 2022-11-03 | $179.64M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $54.49M 10-Q · filed 2022-08-02 | $114.69M 10-Q · filed 2022-08-02 | $153.80M derived: sum of 3 quarters · filed 2022-08-02 | $189.81M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $60.19M 10-Q · filed 2022-05-10 | $99.30M derived: sum of 2 quarters · filed 2022-05-10 | $135.31M derived: sum of 3 quarters · filed 2022-05-10 | $143.50M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $39.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $75.12M derived: sum of 2 quarters · filed 2022-03-15 | $83.31M derived: sum of 3 quarters · filed 2022-03-15 | $89.02M 10-K · filed 2022-03-15 |
| 2020-09-30 | $36.01M 10-Q · filed 2021-11-16 | $44.20M derived: sum of 2 quarters · filed 2021-11-16 | $49.91M 10-Q · filed 2021-11-16 | |
| 2020-06-30 | $8.18M 10-Q · filed 2021-08-10 | $13.90M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $5.71M 10-Q · filed 2021-05-13 |